Search Results - "Rodríguez‐Cerdeira, C."

Refine Results
  1. 1
  2. 2

    Delusional infestation by Rodríguez-Cerdeira, C, Sánchez-Blanco, E, Sánchez-Blanco, B, Carnero-Gregorio, M

    Published in The American journal of emergency medicine (01-02-2017)
    “…[...]6 patients (2, 6, 8, 14, 23, and 24) attributed the relief of the problem to topical dermatological treatment. [...]as reported by Lee (2008) [7],…”
    Get full text
    Journal Article
  3. 3

    Congenital Syphilis in the 21st Century by Rodríguez-Cerdeira, C, Silami-Lopes, V.G

    Published in Actas dermo-sifiliográficas (English ed.) (01-10-2012)
    “…Abstract While the prevalence of congenital syphilis continues to be low throughout most of the developed world, there has been a slight resurgence of the…”
    Get full text
    Journal Article
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8

    A quarter of a century with AIDS by Rodríguez-Cerdeira, C, Cruces, M J, Taboada, J A

    Published in The open AIDS journal (2011)
    “…In Northwestern Spain (NWS), the annual incidence of AIDS diagnoses increased from 1984 (when the first case was diagnosed) until 1996. However, since 1996,…”
    Get full text
    Journal Article
  9. 9

    Dermatophytosis caused by Nannizzia nana by Porras-López, C., Martínez-Herrera, E., Frías-De-León, M.G., Moreno-Coutiño, G., del Rocío Reyes-Montes, M., Arenas, R., González-Cespón, J.L., Rodríguez-Cerdeira, C.

    Published in Journal de mycologie médicale (01-06-2021)
    “…[Display omitted] •We provide three rare cases by N. nana.•The antifungal therapy was terbinafine 250 oral via.•Infrequent infection often…”
    Get full text
    Journal Article
  10. 10

    The Role of IL-33 in Host Response to Candida albicans by Arenas, R., Sánchez-Blanco, B., Lopez-Bárcenas, A., Rodriguez-Cerdeira, Carmen

    Published in TheScientificWorld (01-01-2014)
    “…Background. Interleukin (IL) 33 is a recently identified pleiotropic cytokine that influences the activity of multiple cell types and orchestrates complex…”
    Get full text
    Journal Article
  11. 11

    Study on Certain Biomarkers of Inflammation in Psoriasis Through "OMICS" Platforms by Rodríguez-Cerdeira, C, Molares-Vila, A, Sánchez-Blanco, E, Sánchez-Blanco, B

    Published in The open biochemistry journal (2014)
    “…In recent years, research on psoriasis has focused on the identification of biomarkers for the diagnosis, pathogenesis, prognosis, or therapeutic response of…”
    Get full text
    Journal Article
  12. 12

    Systemic Fungal Infections in Patients with human inmunodeficiency virus by Rodríguez-Cerdeira, C, Arenas, R, Moreno-Coutiño, G, Vásquez, E, Fernández, R, Chang, P

    Published in Actas dermo-sifiliográficas (English ed.) (01-01-2014)
    “…Abstract Histoplasmosis is a systemic infection caused by the dimorphic fungus Histoplasma capsulatum . In immunocompromised patients, primary pulmonary…”
    Get full text
    Journal Article
  13. 13
  14. 14

    Systemic fungal infections in patients with human inmunodeficiency virus by Rodríguez-Cerdeira, C, Arenas, R, Moreno-Coutiño, G, Vásquez, E, Fernández, R, Chang, P

    Published in Actas dermo-sifiliográficas (English ed.) (01-01-2014)
    “…Histoplasmosis is a systemic infection caused by the dimorphic fungus Histoplasma capsulatum. In immunocompromised patients, primary pulmonary infection can…”
    Get full text
    Journal Article
  15. 15

    Biosimilars in Dermatology: Current Situation (Part I) by Puig, L, Carretero, G, Daudén, E, Ferrándiz, C, Marrón, S E, Martorell, A, Pérez-Suárez, B, Rodriguez-Cerdeira, C, Ruiz-Villaverde, R, Sánchez-Carazo, J L, Velasco, M

    Published in Actas dermo-sifiliográficas (English ed.) (01-09-2015)
    “…The first biosimilar version of a biologic agent used to treat psoriasis (infliximab) entered the Spanish market on February 16 of this year, and more…”
    Get full text
    Journal Article
  16. 16

    Biosimilars in Dermatology: Current Situation (Part II) by Puig, L, Carretero, G, Daudén, E, Ferrándiz, C, Marrón, S E, Martorell, A, Pérez-Suárez, B, Rodriguez-Cerdeira, C, Ruiz-Villaverde, R, Sánchez-Carazo, J L, Velasco, M

    Published in Actas dermo-sifiliográficas (English ed.) (01-09-2015)
    “…The first biosimilar version of a biologic agent used to treat psoriasis (infliximab) entered the Spanish market on February 16 of this year, and more…”
    Get full text
    Journal Article
  17. 17

    Biosimilars in Dermatology: Current Situation (Part I) by Puig, L, Carretero, G, Daudén, E, Ferrándiz, C, Marrón, S.E, Martorell, A, Pérez-Suárez, B, Rodriguez-Cerdeira, C, Ruiz-Villaverde, R, Sánchez-Carazo, J.L, Velasco, M

    Published in Actas dermo-sifiliográficas (English ed.) (01-09-2015)
    “…Abstract The first biosimilar version of a biologic agent used to treat psoriasis (infliximab) entered the Spanish market on February 16 of this year, and more…”
    Get full text
    Journal Article
  18. 18

    Biosimilars in Dermatology: Current Situation (Part II) by Puig, L, Carretero, G, Daudén, E, Ferrándiz, C, Marrón, S.E, Martorell, A, Pérez-Suárez, B, Rodriguez-Cerdeira, C, Ruiz-Villaverde, R, Sánchez-Carazo, J.L, Velasco, M

    Published in Actas dermo-sifiliográficas (English ed.) (01-09-2015)
    “…Abstract The first biosimilar version of a biologic agent used to treat psoriasis (infliximab) entered the Spanish market on February 16 of this year, and more…”
    Get full text
    Journal Article
  19. 19
  20. 20